Atinary is thrilled to announce our latest collaboration with the lab of Prof. Rogelio Hernández-López at Stanford University, leveraging Atinary’s no-code AI platform, SDLabs, to advance T cell engineering. This collaboration aims to accelerate the design and optimization of next-generation synthetic circuits for cell therapies, enhancing efficacy while minimizing toxicity.

CAR-T cell therapy is a key advancement in cancer treatment. It involves modifying T cells which enable them to recognize and bind to specific proteins on cancer cells. The challenge lies in optimizing CAR-T cells to attack only tumors while minimizing damage to healthy tissue. By leveraging Atinary’s AI technology, Stanford researchers are systematically exploring large design spaces to accelerate the discovery of optimal synthetic circuit configurations that enhance selectivity and therapeutic potential.

Dr. Rogelio Hernández-López, Assistant Professor of Bioengineering and of Genetics, highlights the impact of SDLabs in this research:

“We are using Atinary’s AI platform (SDLabs) as a powerful approach to explore high-dimensional spaces in synthetic circuits for immunotherapies. With these AI-driven methods, we aim to find novel circuit designs that could enhance selectivity and therapeutic efficacy for immuno-oncology”

The project focuses on designing synthetic circuits T cells with enhanced selectivity, ensuring they target cancer cells with high antigen density while sparing healthy cells. Current CAR-T therapies fail to differentiate between varying antigen levels, highlighting the need for precision engineering to improve safety and efficacy. This innovative approach extends to critical applications in ovarian, breast, and lung cancer treatments, potentially transforming patient outcomes.

This collaboration underscores Atinary’s mission to democratize AI-driven R&D, accelerating breakthroughs in biotech, healthcare, and beyond. While Atinary continues to support researchers with cutting-edge tools, its AI technology is designed to scale seamlessly for leading scientists seeking to optimize complex biological systems and accelerate research and development.

We are proud to support Stanford University’s pioneering research and look forward to the transformative advancements this partnership will bring to T cell therapies and beyond.

Hernández-López Lab: https://www.hl-lab.org

Atinary Technologies: https://atinary.com/